IP Library Granted Patent US 8,815,591
Granted Patent B2
US 8,815,591 · App. 13/646,995 · Granted Aug 26, 2014

Mesoderm and definitive endoderm cell populations

Inventors: Gordon M. Keller (Toronto, CA); Paul Gadue (New York, NY)
Assignee: Icahn School of Medicine at Mount Sinai
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,815,591
App. No.
13/646,995
Granted
Aug 26, 2014
Kind
B2
Abstract

The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy. The present invention further provides a method of generating hepatocytes, cell populations enriched for hepatocytes, and a method of hepatocyte replacement therapy.

Claims (10)

1. A method of making a cell population enriched for endoderm cells comprising culturing embryonic stem cells in the presence of serum for a time sufficient to provide brach + /HNF3β + cells, and culturing said brach + /HNF3β + cells in the presence of activin or nodal and an inhibitor of Wnt signaling for a time sufficient to provide a cell population enriched for endoderm cells.

2. The method of claim 1 wherein the brach + /HNF3β + cells are cultured in the absence of serum.

3. The method of claim 1 wherein the time sufficient to provide brach + /HNF3β + is about three to about 4 days.

4. The method of claim 1 wherein the time sufficient to provide a cell population enriched for endoderm cells is at least about one day.

5. The method of claim 1 wherein the cells are human cells.

6. The method of claim 1 wherein the concentration of activin is at least about 30 ng/ml.

7. The method of claim 1 wherein the concentration of activin is about 100 ng/ml.

8. The method of claim 1 wherein the inhibitor of Wnt signaling is Wnt-I or DKK-1.

9. The method of claim 1 wherein the inhibitor of Wnt signaling is DKK-1 and the concentration of DKK-1 is at least about 30 ng/ml.

10. The method of claim 1 wherein the inhibitor of Wnt signaling is DKK-1 and the concentration of DKK-1 is about 100 ng/ml.

Assignments (1)
CHANGE OF NAME Recorded Jul 18, 2014
From: MOUNT SINAI SCHOOL OF MEDICINE
To: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Reel/Frame 033360/0919 →
Continuity (3)
Continuation 11993432
Continuation 11165930 · Jun 24, 2005
Related Publication 20130095568A1 · Apr 18, 2013